• Precision BioSciences reshuffled its senior leadership team, effective Aug. 1, 2026.
• Chief Financial Officer Alex Kelly was promoted to a newly created Chief Operating Officer role, overseeing key customer-facing functions.
• Naresh Tanna, vice president of investor relations and chief of staff to the CEO, was named Chief Financial Officer, responsible for corporate finance, reporting, investor relations.
• Chief Development Officer Cindy Atwell remains in charge of clinical development for PBGENE-HBV and PBGENE-DMD.
• Chief Scientific Officer Cassie Gorsuch will lead all research functions, including translational sciences and next-generation programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260727263231) on July 27, 2026, and is solely responsible for the information contained therein.